Table 2.
Demographic and clinical characteristics of PD and HV participants
| Variable | PD n = 122 |
HV n = 122 |
p value a |
|---|---|---|---|
|
| |||
| Age, years | |||
| mean (sd) | 68.7 (7.2) | 69.1 (7.0) | .660 |
| range | 51.8 – 84.8 | 50.9 – 83.9 | |
| Education, years | |||
| mean (sd) | 16.4 (2.4) | 16.9 (2.3) | .097 |
| range | 12 – 20 | 12 – 20 | |
| Sex | |||
| n, % male | 55, 45.1 | 55, 45.1 | 1.00 |
| MoCA | |||
| mean (sd) | 27.1 (2.0) | 27.2 (2.1) | .663 |
| range | 22 – 30 | 20 – 30 | |
| APOE ε4 allele | |||
| n, % ε4+ | 26, 21.3 | 30, 24.6 | .543 |
| GDS-15 total score | |||
| mean (sd) | 5.0 (1.7) | 4.6 (1.9) | .038 |
| range | 0 – 12 | 0 – 10 | |
| Motor symptom duration, years b | |||
| mean (sd) | 6.9 (4.4) | ||
| range | 0.5 – 23.3 | ||
| MDS-UPDRS part III | |||
| mean (sd) | 22.6 (10.6) | ||
| range | 5 – 62 | ||
| LEDD, mg/d | |||
| mean (sd) | 589.2 (493.4) | ||
| range | 0 – 2886.9 | ||
| % no PD medication | 9.0% | ||
| % low dose PD medication (</=400 mg/d) | 27.9% | ||
| % medium dose PD medication (>400, <1200 mg/d) | 50.8% | ||
| % high dose PD medication (>=1200 mg/day) | 12.3% | ||
a
P values based on t tests for continuous variables and chi-square tests for categorical variables
b
Motor symptom duration measured from the time the participant reported first motor symptoms
Abbreviations: APOE, apolipoprotein E; GDS-15, 15 item Geriatric Depression Scale; HV, healthy volunteers; LEDD, levodopa equivalent daily dose; MDS-UPDRS, United Parkinson’s Disease Rating Scale, Movement Disorder Society revision; MoCA, Montreal Cognitive Assessment; PD, Parkinson’s disease; sd, standard deviation